Davis George Eric's Form 4 filing
Biomarin Pharmaceutical IncBMRN · filed May 30, 2024
- Accession no.
- 0001048477-24-000112
- Filed
- May 30, 2024
- Trade date
- May 28, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.04M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Davis George EricCIK 0001380710 | Officer (EVP, Chief Legal Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 28, 2024 | Common Stock | MOption exerciseAcquired | +40,850 | $63.10 | +$2,577,635 | 97,007 | Direct | |
| May 28, 2024 | Common Stock | SSaleDisposed | −38,071 | $74.46F2 | −$2,834,766.66 | 58,936 | Direct | |
| May 28, 2024 | Common Stock | SSaleDisposed | −2,779 | $75.29F3 | −$209,230.91 | 56,157 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 28, 2024 | Common Stock | MOption exerciseDisposed | −40,850 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price in column 4 is the weighted average price. The purchase price actually received ranged from $74.12 to $74.99. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
Referenced by the price of 1 transaction in Table I.
- F3
The price in column 4 is the weighted average price. The purchase price actually received ranged from $75.00 to $75.735. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
Referenced by the price of 1 transaction in Table I.